Plain-English translation of NCT06014424 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether cannabidiol ()—a naturally derived, highly purified compound—can help reduce agitation in people with Alzheimer's disease. Agitation is a common and distressing symptom that can lead to falls, weight loss, and caregiver exhaustion. Researchers want to see if this medication works better and is safer than current treatment options.
People with Alzheimer's often experience agitation, but current treatments don't work well for everyone and may have safety concerns. This trial exists because there is a real need for safer, more effective ways to manage this symptom and improve quality of life for both patients and their families.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic approximately every 2 weeks for 12 visits over 19 weeks, plus receive weekly phone calls. You'll randomly receive either the medication or a placebo (a dummy pill) for about 9.5 weeks, then switch to the other treatment for the remaining time. Researchers will measure changes in agitation, mood, thinking ability, nutrition, and pain, and will ask your caregiver about any stress or burden they're experiencing.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Canada